What Ambiotis does

Ambiotis SAS is a privately held Contract Research Organization founded in 2007 in Toulouse, France, that operates as the first CRO worldwide dedicated to the active resolution of inflammation. The company combines validated in vitro and in vivo models (arthritis, COPD, allergies, Crohn disease, colitis, obesity/diabetes, peritonitis, skin inflammation) with quantitative lipid analytical capabilities using LC-MS/MS (QTrap 6500+) and GC-FID to measure specialized pro-resolving mediators (resolvins, protectins, lipoxins, maresins), eicosanoids, endocannabinoids, fatty acids, and skin lipids. More than 50% of its activity is invested in R&D, and it has acquired 10+ years of focused expertise in inflammation resolution pharmacology, a field pioneered by Pr Charles Serhan at Harvard Medical School.

The company generates revenue through fee-for-service contract research delivered to pharmaceutical and biotech firms (proof of concept, mechanism of action validation, biomarker monitoring), dermo-cosmetic companies (efficacy validation of actives using cellular models and skin explants), nutraceutical/food ingredient suppliers (health-claim support), clinical trial sponsors (FDA-validated analytical methods for lipid biomarker monitoring), and, since 2021, animal health companies. Pricing is quote-based and project-specific, with multi-year contracts characteristic of preclinical drug development collaborations. Go-to-market is executed through direct enterprise engagement, supplemented by presence at industry conferences (Vitafoods, Vivaness, ESDR, Keystone, NYAS) and scientific publications.

Ambiotis has a small team (1-10 employees) led by CEO Marc Dubourdeau, PhD, and operates independently with no disclosed external investors or parent company. Public and EU/regional funding (Horizon 2020 ImmunAID grant, Région Occitanie, Incubateur Mipy) supplements commercial revenue. Notable commercial collaborations include Gattefossé, Laboratoires Clarins, Roquette, genOway, Biologische Heilmittel Heel GmbH, OSE Immunotherapeutics (co-developer of OSE-230, a first-in-class pro-resolving antibody published in Science Advances 2021), and PK MED.

Name

Ambiotis

Legal name

Ambiotis SAS

Website

https://ambiotis.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Ambiotis is a Toulouse-based CRO founded in 2007 and the first worldwide dedicated to inflammation resolution, providing preclinical assays, lipid analytical services, and clinical biomarker measurement to pharmaceutical, dermo-cosmetic, nutraceutical, clinical trial, and animal health clients.

Ownership category

akta.pro rank

Product category

Contract Research Services (Preclinical Inflammation Resolution Research)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Metabolomics & Lipidomics Services (HLAGANAG)

Keywords

• Inflammation resolution research
• Lipid analytical services
• Contract research organization
• Specialized pro-resolving mediators
• Preclinical efficacy studies

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: Ambiotis provides fee-for-service research contracts to evaluate molecules at preclinical or clinical stages. Services include analytical packages (sample analysis), model-based packages (compound evaluation), customized development, and scientific consulting. Revenue is generated through project-based contracts with pharmaceutical, cosmetic, nutraceutical, and animal health companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ambiotis is a Contract Research Organization that delivers inflammation resolution research services and lipid analytical services to pharmaceutical, biotech, dermo-cosmetic, nutraceutical, clinical trial, and animal health clients. The company evaluates the potential of molecules at preclinical or clinical stages using validated cell and animal models combined with LC-MS/MS and GC-FID analytical measurement of specialized pro-resolving mediators, eicosanoids, endocannabinoids, fatty acids, and skin lipids. Services are tailored to each client through structured collaboration and delivered with final scientific reports and milestone-based execution.

Product overview

Ambiotis is a Contract Research Organization (CRO) offering a unified portfolio of inflammation research and lipid analytical services. The company provides services adapted to pharmaceutical, dermo-cosmetic, agro-food/nutraceutical industries, and animal health sectors to evaluate the potential of molecules at preclinical or clinical stages. The core offerings include inflammation assays, lipid analytical services (SPM quantification, eicosanoid profiling, fatty acid analysis), in vitro and in vivo proof-of-concept studies, and clinical assay services. These are delivered through a technology platform combining cell/animal models with analytical measurement capabilities for deciphering mechanisms of action and providing biomarker monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

• Inflammation Assays CRO services providing inflammation assays using cell and animal models to evaluate the potential of molecules at preclinical or clinical stages of development, with a focus on the active resolution of inflammation. Therapeutic areas covered include arthritis, COPD, allergies, Crohn disease, colitis, obesity/diabetes, and peritonitis.
• Lipid Analytical Services Quantitative lipid analysis using LC-MS/MS and GC-FID technologies to measure specialized pro-resolving mediators (SPMs), eicosanoids (prostaglandins, thromboxanes, leukotrienes), endocannabinoids, fatty acids, cholesterol, sterols, triglycerides, and skin lipids in various biological samples.
• Biotech & Pharma Services Contract research services for pharmaceutical and biotechnology companies delivering preclinical proof-of-concept studies and mechanism-of-action investigations for therapeutic areas including arthritis, COPD, allergies, Crohn disease, colitis, obesity/diabetes, and peritonitis.
• Dermo-Cosmetics Services Efficacy validation services for cosmetic active ingredients using cellular models and skin explants supporting market-oriented positioning in cutaneous protection, anti-pollution, anti-aging, defense, and acne treatment applications.
• Nutraceutics Services Biological evaluations for nutraceutical and food ingredient companies to substantiate immuno-modulatory claims, disease prevention benefits, and maintenance of healthy balance through resolution pathways.
• Clinical Assays Precise and quantitative monitoring of lipid mediators (eicosanoids, SPMs, endocannabinoids) in various human biological samples for clinical studies, with analytical methods validated according to FDA guidelines to support biomarker monitoring, translational studies, and patient stratification.
• Animal Health Services Biological evaluations of products for animal health and well-being, including nutritional ingredients and veterinary products, ranging from screening assays to clinical trials using validated models translated from human inflammation research.

Quantifiable outcome

• Detection limits lowered by up to 10 times for most metabolites with new LC-MS/MS system
• +2 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and standard.

• European Union Horizon 2020coreStrategic or Co-development Partner · 1 January 2018Ambiotis is involved in the ImmunAID project (Grant Agreement N°779295), a large-scale research initiative funded by the EU's Horizon 2020 program. The project focuses on optimizing diagnostic, classification and clinical management of patients with auto-inflammatory disorders (AID). Ambiotis is responsible for assessing resolution markers by metabololipidomics using multiomics and bioinformatic approaches.
• GattefossécoreStrategic or Co-development Partner · 1 January 2018Ongoing fruitful collaboration with Gattefossé, a major expert in plant extraction and lipochemistry. Jointly developed a new efficacy model for inflammatory resolution that was key to developing an innovative active ingredient. Companies co-presented at IID 2018 and collaborated on investigating inflammation resolution pathways in skin explants.
• Laboratoires ClarinscoreStrategic or Co-development Partner · 1 January 2018Collaboration with Clarins on skin research, including poster presentation at SPIM 2018 on circadian rhythms modulation in senescent skin fibroblasts. Investigated the link between skin functions and circadian rhythms in aging context.
• Biologische Heilmittel Heel GmbHcoreStrategic or Co-development Partner · 1 January 2018Collaboration on HE-100 product evaluation for inflammation resolution. Research findings were presented at NYAS 2018 symposium 'Resolution of Inflammation, Infection and Tissue Regeneration'. Demonstrated successful completion of research program.
• RoquettestandardStrategic or Co-development PartnerGlobal leader in plant-based ingredients for food, nutrition and health markets. Collaboration to assess anti-inflammatory properties of products, with appreciation for quality of results and deadline respect.
• genOwaystandardStrategic or Co-development PartnerCollaboration on discovery and preclinical models. genOway appreciated the scientific discussion quality on study design, customer support, and thoroughness of shared results.
• OSE ImmunotherapeuticscoreStrategic or Co-development PartnerAmbiotis actively participated in the development of OSE-230, an antibody targeting resolution of inflammation pathways. ChemR23 agonist antibody that promotes efferocytosis and reduces neutrophil apoptosis. Published in Science Advances 2021 as a first-in-class drug with pro-resolutive properties.
• PK MEDstandardStrategic or Co-development PartnerPre-clinical stage biopharmaceutical company developing innovative local treatments. Ongoing collaboration on inflammatory phenomena projects with high professionalism, scientific expertise, and responsiveness.
• Lucas Meyer CosmeticsstandardStrategic or Co-development PartnerCollaborative research on targeting inflammation and specialized pro-resolving mediators to reinforce barrier function and scalp homeostasis. Presented at ESDR 2022.
• IMACTIV 3DstandardTechnology or IntegrationPartnership with image analysis specialist for High Content Imaging system used in phagocytosis assays. IMACTIV 3D provides quantification expertise for kinetic monitoring of phagocytosis.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Evotec SE: Evotec is a drug-discovery CRO offering inflammation and immunology research services including preclinical models and biomarker analytics. Adjacent to Ambiotis in inflammation pharmacology but with broader integrated discovery capabilities.
• ICON plc: ICON is a global clinical CRO offering bioanalytical and biomarker services for clinical trials. Comparable to Ambiotis's clinical assays / FDA-validated biomarker work, though operating at much larger scale and across many therapeutic areas.
• Eurofins Scientific: Eurofins is a global life-sciences testing group with extensive lipidomics, biomarker, and CRO capabilities across pharma and consumer health. A broad incumbent offering overlapping inflammation and lipid analytical services at much greater scale and geographic reach.
• Charles River Laboratories: Charles River is a major preclinical CRO providing safety, efficacy, and biomarker services to pharma and biotech. Its discovery/safety services and inflammation models partially overlap with Ambiotis's preclinical proof-of-concept offerings.
• SGS Life Sciences: SGS offers clinical research and bioanalytical services including biomarker analysis for pharma and consumer health. Provides an alternative destination for lipid biomarker clinical work that Ambiotis also pursues.

Emerging players

• Resolve BioSciences: Resolve BioSciences is an emerging spatial omics / molecular analytics company extending into inflammation and tissue biology applications. Adjacent to Ambiotis's inflammation biology work, though with different underlying technology.
• QPS Holdings: QPS is a mid-sized CRO with bioanalytical and biomarker capabilities serving pharma clinical trials. Overlaps with Ambiotis's clinical biomarker monitoring services, particularly in lipid and inflammation-related endpoints.
• Bioneer: Bioneer is a Korean life-science services provider offering lipidomics, oligonucleotides, and molecular diagnostics services. Comparable as a regional lipidomics-focused lab service with research and clinical applications.

Direct peers

• Cayman Chemical: Cayman Chemical provides lipid mediators, eicosanoids, and SPM reference standards plus associated analytical services. Overlaps with Ambiotis's SPM quantification and eicosanoid profiling work, particularly for clients needing standardized lipid mediator measurements.
• Metabolon: Metabolon is a specialty metabolomics CRO offering untargeted metabolite profiling and lipidomics services to pharma, nutrition, and academic clients. Directly comparable to Ambiotis's lipid analytical and biomarker services, though at materially larger scale and broader analyte scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xlinkedin.com/company/ambiotis

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambiotis